However, due to the clinical limitations pertaining to (1) its level of expression in BC at a much lower scale than in thyroid and (2) the safety concerns in terms of protecting the patient’s normal thyroid function, NIS gene therapy trials are not yet done in the clinic. Here, SLC5A5 is linked to breast cancer.